Seeking Alpha

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

TORONTO and HAIFA, Israel, Feb. 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA) (FSE: J90) (NRX.V), known as "NurExone," is pleased to announce the initiation of the Orphan Drug ...
The Columbian

Just months after public offering, Absci heading for clinical trials with a biologic drug candidate

After raising nearly $90 million in its recent public offering, Vancouver-based Absci is advancing toward clinical trials for what would be its first biologic drug candidate. Absci uses its database ...
Seeking Alpha

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

TORONTO and HAIFA, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”) is pleased to announce significant ...
Digital Journal

How biologics CDMOs are shaping early-stage drug development strategy?

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...
The Columbian

Vancouver’s Absci reports loss for 2023 but still moving forward with ‘AI-driven biologic drug discovery’

Founder and CEO Sean McClain poses next to a mural in a lab at Absci Corp., headquartered in Vancouver. (The Columbian files) Absci reported a loss for 2023, but the Vancouver-based company also ...
GEN

Biologics Drug Development Gets an Upgrade with Humanized Animal Models

While humanized animal models are relatively new to drug development compared to their non-humanized counterparts, they are critical tools in the landscape of biologic drug development. Their success ...
techtimes

Key Challenges and Solutions in Drug Substance Manufacturing

Drug Substance manufacturing is a critical component of pharmaceutical production, requiring precise processes, rigorous quality control, and innovative solutions to overcome various challenges. From ...